Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback